The profile is currenly unclaimed by the seller. All information is provided by CB Insights.

decimmune.com

Founded Year

2001

Stage

Grant - II | Alive

Total Raised

$10.54M

Last Raised

$3M | 8 yrs ago

About Decimmune Therapeutics

DecImmune Therapeutics is developing a novel monoclonal antibody, DeciMab, aimed at preventing tissue damage and preserving organ function in a range of vascular inflammatory diseases. The company's approach is based on the discovery of an innate IgM-mediated auto-immune pathway that is triggered by vascular injury in conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. This pathway, dubbed N2, can initiate a cascade of tissue damaging events leading to loss of organ function.

Decimmune Therapeutics Headquarter Location

47 Thorndike Street Suite B1-1

Cambridge, Massachusetts, 02141,

United States

617-278-6655

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Decimmune Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Decimmune Therapeutics is included in 2 Expert Collections, including Diabetes.

D

Diabetes

1,750 items

B

Biopharma Tech

838 items

Decimmune Therapeutics Patents

Decimmune Therapeutics has filed 6 patents.

patents chart

Application Date

Grant Date

Title

Related Topics

Status

3/12/2014

8/9/2016

Immune system, Immunology, Complement system, Clusters of differentiation, Glycoproteins

Grant

Application Date

3/12/2014

Grant Date

8/9/2016

Title

Related Topics

Immune system, Immunology, Complement system, Clusters of differentiation, Glycoproteins

Status

Grant

Latest Decimmune Therapeutics News

DecImmune Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile Report Updated 13042018 Prices from USD $250

Aug 19, 2018

16:58 EDT 19 Aug 2018 | BioPortfolio Reports Summary DecImmune Therapeutics Inc DecImmune is a developer of monoclonal antibody preventing tissue damage and preserving organ function in vascular inflammatory diseases. The company offers discovery of innate IgMmediated autoimmune pathway that is triggered by vascular injuries. Its IgMmediated autoimmune pathway is used in vascular injury conditions such as diabetic nephropathy, sickle cell disease, and myocardial infarction. DecImmune's research and development services comprise preclinical proofofconcept studies, indication studies, intellectual property and partnering services. The company also develops therapeutics for treating second degree burns and prevents reperfusion injury in transplant patients. DecImmune is headquartered in Cambridge, Massachusetts, the US. DecImmune Therapeutics Inc Pharmaceuticals Healthcare Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions MAs, partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, subsector and regions. GlobalData derived the data presented in this report from proprietary inhouse Pharma eTrack deals database, and primary and secondary research. Scope Financial Deals Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships. Deals by Year Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period. Deals by Type Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc. Deals by Region Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America. Deals by Subsector Chart and table showing information on the number of deals and value reported by the company, by subsector. Major Deals Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's major public companies key financial metrics and ratios. Business Description A brief description of the company's operations. Key Employees A list of the key executives of the company. Important Locations and Subsidiaries A list and contact details of key centers of operation and subsidiaries of the company. Key Competitors A list of the key competitors of the company. Key Recent Developments A brief on recent news about the company. Reasons to Buy Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period. Understand the company's business segments' expansion / divestiture strategy The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy. Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios. Equip yourself with detailed information about the company's operations to identify potential customers and suppliers. The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors. Stay uptodate on the major developments affecting the company Recent developments concerning the company presented in the profile help you track important events. Gain key insights into the company for academic or business research Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs. Note*: Some sections may be missing if data is unavailable for the company. Related Biotechnology, Pharmaceutical and Healthcare News

  • When was Decimmune Therapeutics founded?

    Decimmune Therapeutics was founded in 2001.

  • Where is Decimmune Therapeutics's headquarters?

    Decimmune Therapeutics's headquarters is located at 47 Thorndike Street, Cambridge.

  • What is Decimmune Therapeutics's latest funding round?

    Decimmune Therapeutics's latest funding round is Grant - II.

  • How much did Decimmune Therapeutics raise?

    Decimmune Therapeutics raised a total of $10.54M.

  • Who are the investors of Decimmune Therapeutics?

    Investors of Decimmune Therapeutics include National Institutes of Health, Astellas Venture Management, Broadview Ventures and Amgen Ventures.

  • Who are Decimmune Therapeutics's competitors?

    Competitors of Decimmune Therapeutics include Dare Bioscience, Iconic Therapeutics, Endocyte, Immutep, REGiMMUNE and 13 more.

You May Also Like

S
Stem Cells Bank

Stem Cells Bank Biotechnological Company engaged in development of autovaccines for treating oncological diseases and tuberculosis, produced on the basis of autologous dendritic cells (cells extracted from the organism of the very patient to be given the vaccine). In the framework of thus project it is planned to develop and launch a vaccine for treating oncological diseases and tuberculosis, produced on the basis of cells extracted from the organism of the very patient to be given the vaccine.

D
Dare Bioscience

Dare Bioscience is a healthcare company committed to the development and commercialization of innovative products in women's reproductive health. We believe there is an unmet need globally for new product candidates that expand options, improve outcomes and are easy to use. By advancing these products, we seek to expand choices and to make a difference in the lives of women worldwide.

L
LeukoSight

LeukoSight Inc. is an early stage biotechnology company developing a line of therapeutics that can be used to treat autoimmune and inflammatory diseases.

moksha8 Logo
moksha8

Moksha8 is a specialty pharmaceutical company focused on licensing, marketing and distributing established therapeutics in Brazil and Mexico.

V
Vybion

Vybion is a developer and manufacturer of recombinant proteins for therapeutic and diagnostic applications. It uses its technologies along with a highly skilled staff to develop therapeutics, vaccines, diagnostics and bioavailability for pharmaceutical and biotechnology companies.

A
American Stem Cell

ASC is a privately held biotechnology company dedicated to the development and commercialization of enabling technologies to enhance and expand the therapeutic potential of stem cell therapies. The key technology platforms (ASC-101 and ASC-201) are designed to improve the homing and engraftment of stem cells to target organs and increase their therapeutic potential for cancer patients. Additionally, these platforms have the potential to enhance stem cell treatment of inflammation from chemotherapy/radiation, solid tumors, autoimmune diseases, and ischemic diseases including myocardial infarction and stroke. ASC has strategic partnerships with medical research institutions including the University of Texas M.D. Anderson Cancer Center, the Oklahoma Medical Research Foundation, University of California, the Burnham Institute, Indiana University, Rush Presbyterian and VidaCord Technologia Biomedica.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.